Nanobiotix S A's Comment on Sales, Marketing and Customers
Pharmaceutical products entering the South Korean market must comply with regulatory requirements set by the Ministry of Food and Drug Safety (MFDS). Foreign companies are required to appoint local agents to facilitate market entry and ensure adherence to MFDS standards, including post-marketing surveillance obligations. The MFDS offers expedited approval pathways for Orphan Drugs, Innovative Drugs, and Conditional Approvals.
Nanobiotix S.A. operates subsidiaries in Delaware and Germany, with corporate headquarters and a manufacturing facility located in Paris, France. The Paris facility produces JNJ1900 (NBTXR3) for clinical trial purposes. The company’s entities include Nanobiotix Corp., Nanobiotix Germany GmbH, and Nanobiotix S.A.
NBTXR3: A Nanoparticle-Based Breakthrough in the Treatment of Stage Three Lung CancerLung cancer remains a significant health concern worldwide, with non-small cell lung cancer (NSCLC) being the most common type. While there have been several advancements in the treatment of NSCLC, there is still an urgent need for more effective therapeutic approaches for patients with advanced-stage disease. In a recent announcement, NANOBIOTIX, a late-clinical stage biotechnology company, has revealed that the US Food and Drug Administration (FDA) has accepted their protocol for a Phase 2 study evaluating NBTXR3 in patients with stage 3, unresectable NSCLC. This development holds great promise for improving treatment outc...
Nanobiotix S A’s Comment on Sales, Marketing and Customers
Pharmaceutical products entering the South Korean market must comply with regulatory requirements set by the Ministry of Food and Drug Safety (MFDS). Foreign companies are required to appoint local agents to facilitate market entry and ensure adherence to MFDS standards, including post-marketing surveillance obligations. The MFDS offers expedited approval pathways for Orphan Drugs, Innovative Drugs, and Conditional Approvals.
Nanobiotix S.A. operates subsidiaries in Delaware and Germany, with corporate headquarters and a manufacturing facility located in Paris, France. The Paris facility produces JNJ1900 (NBTXR3) for clinical trial purposes. The company’s entities include Nanobiotix Corp., Nanobiotix Germany GmbH, and Nanobiotix S.A.
Sources:
Nanobiotix S a’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Nanobiotix S a’s corporate clients.
For your research, we’ve provided 9 tables on Nanobiotix S a corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
69.59 %